scholarly journals Self-management of overactive bladder at home using transcutaneous tibial nerve stimulation: a qualitative study of women’s experiences

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ciara M. E. Daly ◽  
Lynette Loi ◽  
Jo Booth ◽  
Dalia Saidan ◽  
Karen Guerrero ◽  
...  

Abstract Background Transcutaneous tibial nerve stimulation (TTNS) has been used to treat overactive bladder (OAB), however patient experiences and views of this treatment are lacking. The aim of this study was to explore women’s experiences of OAB and TTNS treatment and the perceived factors influencing participation and adherence. Methods Semi-structured, individual interviews conducted as part of a mixed-methods, randomised, feasibility trial of self-managed versus HCP-led TTNS. Interviews were audio recorded and transcribed verbatim. Reflexive thematic analysis was undertaken using Booth et al. (Neurourol Urodynam. 2017;37:528–41) approach. Results 16 women were interviewed, 8 self-managing TTNS at home and 8 receiving TTNS in twice-weekly hospital clinic appointments. Women self-managing OAB considered TTNS easy to administer, flexible and favourably ‘convenient’, especially when the participant was bound by work and other life commitments. In contrast to OAB symptoms ‘dominating life’, self-managing bladder treatment was empowering and fitted around home life demands. Flexibility and control engendered by self-management, facilitated women’s willingness to participate in TTNS. Women attending a hospital clinic for TTNS enjoyed the social aspects but found the routine appointments constrained their lives. Motivation to continue TTNS in the longer term was dependent on perception of benefit. Conclusions This study provides novel insights into women’s experiences of self-managing their OAB using TTNS compared to HCP-led management in the clinical setting. It highlights positive experiences self-managing TTNS at home and a willingness to continue in the longer term, facilitated by ease of use and convenience. Trial Registration 1/11/2018: ClinicalTrials.gov Identifier: NCT03727711.

2018 ◽  
Vol 36 (9) ◽  
pp. 1455-1460 ◽  
Author(s):  
Pierre-Adrien Leroux ◽  
Elena Brassart ◽  
Souhil Lebdai ◽  
Abdel-Rahmène Azzouzi ◽  
Pierre Bigot ◽  
...  

2012 ◽  
Vol 53 (7) ◽  
pp. 483 ◽  
Author(s):  
Miguel Angel Arrabal-Polo ◽  
Francisco Palao-Yago ◽  
Iluminada Campon-Pacheco ◽  
Maribel Martinez-Sanchez ◽  
Armando Zuluaga-Gomez ◽  
...  

2019 ◽  
Vol 123 (5A) ◽  
pp. E20-E28 ◽  
Author(s):  
Janek Salatzki ◽  
Martina D. Liechti ◽  
Eleonora Spanudakis ◽  
Gwen Gonzales ◽  
Joanne Baldwin ◽  
...  

2017 ◽  
Vol 25 (4) ◽  
pp. 245-54
Author(s):  
Elita Wibisono ◽  
Harrina E. Rahardjo

Overactive bladder (OAB) is a common condition that is experienced by around 455 million people (11% of the world population) and associated with significant impact in patients’ quality of life. The first line treatments of OAB are conservative treatment and anti-muscarinic medication. For the refractory OAB patients, the treatment options available are surgical therapy, electrical stimulation, and botulinum toxin injection. Among them, percutaneous tibial nerve stimulation (PTNS) is a minimally invasive option that aims to stimulate sacral nerve plexus, a group of nerve that is responsible for regulation of bladder function. After its approval by food and drug administration (FDA) in 2007, PTNS revealed considerable promise in OAB management. In this review, several non-comparative and comparative studies comparing PTNS with sham procedure, anti-muscarinic therapy, and multimodal therapy combining PTNS and anti-muscarinic had supportive data to this consideration.


Sign in / Sign up

Export Citation Format

Share Document